Sun Pharmaceutical Industries Q1 Results Revenue $1.3 Billion, Net Profit $300 Million

Sun Pharmaceutical Industries Q1 Results

Sun Pharmaceutical Industries Reported a mix of financial performance indicators for the first quarter of the fiscal year. The company's revenue from operations was ₹44,980.7 million, which is a decrease from the previous quarter's ₹56,391.4 million and slightly lower compared to ₹44,660.7 million from the same quarter last year. The company also earned ₹827.4 million in other income, bringing the total income to ₹45,808.1 million for the quarter.

Sun Pharmaceutical saw a rise in the cost of materials consumed to ₹9,732.3 million from ₹10,558.7 million last quarter in terms of expenses, . Employee benefits expense increased to ₹6,454.8 million, and finance costs were ₹2,160.8 million. The total expenses amounted to ₹43,228.9 million, which is slightly higher than the ₹43,562.4 million in the previous quarter.

Sun Pharmaceutical Industries achieved a profit before tax of ₹2,579.2 million, a decrease from ₹14,017.8 million in the previous quarter. The profit after tax for the quarter was ₹2,378.2 million. Other comprehensive income was positive at ₹165.8 million, leading to a total comprehensive income of ₹2,544.0 million. The earnings per share were ₹1.0. 

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Sun Pharmaceutical Industries Q1 Results Overview

Sun Pharmaceutical saw a decrease in revenue and profit compared to previous periods.

For the first quarter of 2024-2025, Sun Pharmaceutical Industries reported the following financial results:

Sun Pharmaceutical Industries Stock Metrics 

Sun Pharmaceutical Industries’ stock price is currently ₹1,766, and it has a market value of ₹4,23,879 crore. The company’s shares have been as high as ₹1,771 and as low as ₹1,068 in recent times. 

Here is the financial summary in a table format:

Quarterly Results 

Sun Pharmaceutical Industries from December 2023 to June 2024. It covers key metrics such as sales, expenses, and profits. Sales increased from ₹12,381 crores in December 2023 to ₹12,653 crores in June 2024, reflecting a growth trend.

Here are the financial figures for December 2023, March 2024, and June 2024:

About Sun Pharmaceutical Industries 

Sun Pharmaceutical Industries is a major global pharmaceutical company, ranking as the fourth largest in the world. Founded in 1983, the company has grown significantly and now earns $5.4 billion in revenue annually. With over 41,000 employees worldwide, Sun Pharma operates 43 manufacturing facilities and provides affordable, high-quality medicines to more than 100 countries.

Sun Pharmaceutical Industries offers a wide range of products, including generics, branded generics, specialty medicines, and complex technology-intensive products. Their portfolio includes over 2,000 different medicines in various forms such as tablets, capsules, injectables, and creams. They sell more than 30 billion doses each year, covering many medical areas like cardiology, oncology, and dermatology.

Sun Pharma is dedicated to innovation and invests 6-8% of its revenue into research and development each year. They focus on developing advanced products, including liposomal drugs and controlled-release forms. Their R&D team consists of over 2,800 professionals.

Sun Pharmaceutical Industries is a leader in India and has a strong presence in the US and emerging markets like Brazil and Russia. Sun Pharma aims to reach people globally and improve lives with their valued medicines.